{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:03:14Z","timestamp":1791414194625,"version":"4.3.3"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    We evaluated the activity of the novel spiropyrimidinetrione AZD0914 (DNA gyrase inhibitor) against clinical gonococcal isolates and international reference strains (\n                    <jats:italic>n<\/jats:italic>\n                    = 250), including strains with diverse multidrug resistance and extensive drug resistance. The AZD0914 MICs were substantially lower than those of most other currently or previously recommended antimicrobials. AZD0914 should be further evaluated, including\n                    <jats:italic>in vitro<\/jats:italic>\n                    selection,\n                    <jats:italic>in vivo<\/jats:italic>\n                    emergence and mechanisms of resistance, pharmacokinetics\/pharmacodynamics in humans, optimal dosing, and performance, in appropriate randomized and controlled clinical trials.\n                  <\/jats:p>","DOI":"10.1128\/aac.03090-14","type":"journal-article","created":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T10:43:52Z","timestamp":1404211432000},"page":"5585-5588","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":79,"title":["High\n                    <i>In Vitro<\/i>\n                    Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant Neisseria gonorrhoeae Isolates Suggests a New Effective Option for Oral Treatment of Gonorrhea"],"prefix":"10.1128","volume":"58","author":[{"given":"Susanne","family":"Jacobsson","sequence":"first","affiliation":[{"name":"WHO Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections, National Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Clinical Microbiology, \u00d6rebro University Hospital, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Golparian","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections, National Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Clinical Microbiology, \u00d6rebro University Hospital, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Alm","sequence":"additional","affiliation":[{"name":"Infection iMed, AstraZeneca R&amp;D Boston, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Huband","sequence":"additional","affiliation":[{"name":"Infection iMed, AstraZeneca R&amp;D Boston, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mueller","sequence":"additional","affiliation":[{"name":"Infection iMed, AstraZeneca R&amp;D Boston, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgen Skov","family":"Jensen","sequence":"additional","affiliation":[{"name":"Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ohnishi","sequence":"additional","affiliation":[{"name":"National Institute of Infectious Diseases, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Unemo","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections, National Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Clinical Microbiology, \u00d6rebro University Hospital, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Global incidence and prevalence of selected curable sexually transmitted infections\u20142008","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. 2012. Global incidence and prevalence of selected curable sexually transmitted infections\u20142008. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.12.117"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.09.63"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06215.x"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2010.042648"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.176575"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.2807\/ese.16.14.19833-en"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt034"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05760-11"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2807\/ese.16.43.19998-en"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.2807\/ese.15.47.19721-en"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3201\/eid1308.060948","article-title":"Threat to cefixime treatment for gonorrhea","volume":"13","author":"Yokoi S","year":"2007","unstructured":"YokoiSDeguchiTOzawaTYasudaMItoSKubotaYTamakiMMaedaS. 2007. Threat to cefixime treatment for gonorrhea. Emerg. Infect. Dis. 13:1275\u20131277.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00325-11"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.007641-0"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.2807\/ese.16.06.19792-en"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2807\/ese.17.25.20200-en"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1071\/SH13077"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt017"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks162"},{"key":"e_1_3_3_21_2","first-page":"1","volume-title":"Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae","author":"World Health Organization, Department of Reproductive Health and Research","year":"2012","unstructured":"World Health Organization, Department of Reproductive Health and Research. 2012. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae, p 1\u201336. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_22_2","unstructured":"Centers for Disease Control and Prevention. 2012. Cephalosporin-resistant Neisseria gonorrhoeae public health response plan p 1\u201343. Centers for Disease Control and Prevention Atlanta GA."},{"key":"e_1_3_3_23_2","first-page":"1","volume-title":"Response plan to control and manage the threat of multidrug-resistant gonorrhoea in Europe","author":"European Centre for Disease Prevention and Control","year":"2012","unstructured":"European Centre for Disease Prevention and Control. 2012. Response plan to control and manage the threat of multidrug-resistant gonorrhoea in Europe, p 1\u201323. European Centre for Disease Prevention and Control, Stockholm, Sweden."},{"key":"e_1_3_3_24_2","volume-title":"Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother","author":"Huband MD","year":"2013","unstructured":"HubandMDOttersonLGDoigPCGiacobbeRAPateySAGowravaramMBasarabGSMuellerJP. 2013. Benzisoxazoles: in vitro activity of new bacterial DNA gyrase\/topoisomerase IV inhibitors against Gram-positive, fastidious Gram-negative, atypical, and anaerobic bacterial isolates, poster F-1220. Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-011-3557-z"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1021\/cr4003984"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026613666131113153251"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00596-06"},{"key":"e_1_3_3_29_2","volume-title":"Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother","author":"Alm RA","year":"2013","unstructured":"AlmRAKutschkeAOttersonLGLahiriSDMcLaughlinRELewisLASuXHubandMDMuellerJPGardnerH. 2013. Novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae (NG) and Staphylococcus aureus (SA), poster F-1225c. Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp098"},{"key":"e_1_3_3_31_2","volume-title":"CLSI document M100-S24","author":"Clinical and Laboratory Standards Institute","year":"2014","unstructured":"Clinical and Laboratory Standards Institute. 2014 Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA. http:\/\/clsi.org\/blog\/2014\/01\/27\/m100-s24_em100_2014\/."},{"key":"e_1_3_3_32_2","volume-title":"Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother","author":"Huband MD","year":"2013","unstructured":"HubandMDFlammRKRhombergRMuellerJPJonesRN. 2013. In vitro activity of AZD0914: a new benzisoxazole DNA gyrase inhibitor against Neisseria gonorrhoeae, poster F-1225b. Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_3_33_2","first-page":"590","article-title":"Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections","volume":"61","year":"2012","unstructured":"Centers for Disease Control and Prevention. 2012. Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb. Mortal. Wkly. Rep. 61:590\u2013594.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/0956462412472837"},{"key":"e_1_3_3_35_2","unstructured":"European Committee for Antimicrobial Susceptibility Testing. 2014. Breakpoint tables for interpretation of MICs and zone diameters. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/Breakpoint_table_v_4.0.pdf."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03090-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03090-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T12:18:32Z","timestamp":1746274712000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.03090-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1128\/AAC.03090-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.03090-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"2014-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-06-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}